Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

A legfontosabb adatok

Ki végzi
Shionogi
Hol
Durham és Little Rock (Egyesült Államok)Mind a 2 helyszín megnézéseMég 2 másik országban, 2 helyszínen
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
30 fő vett részt
Kezdés
2024. márc. 14.
Befejezés
2025. márc. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • Cefiderocol
  • Standard of Care
A regiszteradat frissítve
2026. március 2.

Ki vehet részt

Életkor
Legfeljebb 3 hónap
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki nem vehet részt

  • Urine output < 1.0 milliliter (mL)/kg/hour within the 24 hours prior to study drug administration on Day 1
  • Receiving renal replacement therapy
  • Received any other investigational medicinal product within 30 days of study drug administration
  • Receiving treatment with a vasopressor at Screening
  • Anticipated need for antibacterial therapy longer than 14 days (example , osteomyelitis or endocarditis); this applies to both study treatment with cefiderocol, as well as adjunctive IV antibacterial treatment for suspected coinfection with Gram-positive organisms or multidrug resistant Gram-negative organisms
  • Documented history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibiotic
  • Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data
  • Has a confirmed or strongly suspected infection at Screening with a pathogen known to be resistant to cefiderocol or only a Gram-positive pathogen or viral, fungal, or parasitic pathogen as the sole cause of infection
  • Suspected or confirmed central nervous system (CNS) infection, including suspected CNS infection who do not have a lumbar puncture (LP) but who are treated for potential CNS infection, evidence suggestive of CNS infection based on LP results (polymorphonuclear pleocytosis, hypoglycorrhachia, and increased protein concentration), regardless of culture results, LP with organisms on Gram stain or culture-positive cerebrospinal fluid; Note: Other protocol-defined Inclusion/Exclusion criteria may apply
  • Serum creatinine value greater than the maximum for GA and PNA shown below within the 24 hours prior to study drug administration on Day 1
  • Neonatal acute kidney injury (AKI), defined as a serum creatinine level greater than 1.5 milligrams per decilieter (mg/dL) (133 micromoles[μmol]/liter [L]) or an increase of 0.3 mg/dL (17 to 27 μmol/L) per day from a previous lower value
  • Acute kidney injury based on an increase in serum creatinine ≥ 0.3 mg/dL within 48 hours from an established baseline value
  • Life expectancy of < 72 hours after enrollment

Egyéb feltételek

  • Eligibility Criteria: Key Inclusion Criteria:
  • Written informed consent has been provided by parent(s) or legally authorized representative(s) in accordance with local regulatory requirements
  • Hospitalized infants from birth to < 3 months (< 90 days) of age at the time written informed consent is provided. Enrollment of premature infants will not be restricted, but they must have a GA ≥ 26 weeks, PNA of 0 to 3 months, and weight of at least 1 kilogram (kg)
  • Require systemic IV antibiotic treatment for suspected or confirmed aerobic Gram-negative infections including, but not limited to, complicated urinary tract infection, complicated intra-abdominal infection, hospital-acquired/ ventilator-associated bacterial pneumonia, and BSI/sepsis
  • For the multiple-dose phase, within 72 hours of the start of potentially effective treatment with SOC antibiotics for the suspected or confirmed primary aerobic Gram-negative infection

Helyszínek itt: Egyesült Államok

Még 2 másik országban, 2 helyszínen

  • Duke UniversityDurham, Egyesült Államok
  • Arkansas Children's HospitalLittle Rock, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary purpose of this study is to understand the pharmacokinetics (PK) of single and multiple doses of cefiderocol in children from birth to less than 3 months of age with suspected or confirmed aerobic Gram-negative bacterial infections.

A vizsgálat 2 csoportja

  • Single-Dose CefiderocolA vizsgált kezelés

    Participants will receive a single dose cefiderocol on Day 1, along with standard of care antibiotics

    Kezelés: Cefiderocol és Standard of Care

  • Multiple-Dose CefiderocolA vizsgált kezelés

    Participants will receive cefiderocol every 8 hours for 5 to 14 days, along with standard of care antibiotics

    Kezelés: Standard of Care

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter, Single-arm, Open-label Study to Assess the Pharmacokinetics, Safety, and Tolerability of Cefiderocol in Hospitalized Pediatric Patients From Birth to < 3 Months of Age With Suspected or Confirmed Aerobic Gram-negative Bacterial Infections
A regiszteradat frissítve
2026. március 2.